European Medicines Agency human medicines committee (CHMP) recommends approval of anakinra for treatment of adults with COVID-19 , EMA
Supporting data from study of 606 hospitalised adults with moderate/severe COVID-19 pneumonia, at risk of severe respiratory failure (suPAR ≥6ng/ml), which showed greater clinical symptom improvement over 28-days in anakinra plus standard of care (SOC) arm vs. placebo plus SOC.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: COVID-19 | European Medicines Agency (EMA) | Health | Pneumonia | Respiratory Medicine | Study